SHEL:LSEShell Plc Analysis
Data as of 2026-03-09 - not real-time
£3,207.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Shell plc is trading near its 52‑week high with a bullish MACD crossover and a RSI of 76, indicating short‑term overbought conditions. The stock’s beta of 0.24 and a 30‑day volatility around 22% suggest modest price swings, while the DCF fair value of ~£4,518 versus the current price of ~£3,207 points to a marginal (PE of 14.3 below the sector average, a robust dividend yield of 3.5% with a payout ratio under 50%, and strong operating cash flow supporting dividend sustainability.
Recent material news highlights the Q4 2025 interim dividend announcement and continued analyst optimism, with a “Buy” consensus from 17 analysts and Morgan Stanley maintaining an “Overweight” stance despite a modest price‑target cut. The surge in oil prices above $100 per barrel is providing an earnings tailwind, while strategic growth wins in renewables and LNG reinforce the longer‑term narrative.
Recent material news highlights the Q4 2025 interim dividend announcement and continued analyst optimism, with a “Buy” consensus from 17 analysts and Morgan Stanley maintaining an “Overweight” stance despite a modest price‑target cut. The surge in oil prices above $100 per barrel is providing an earnings tailwind, while strategic growth wins in renewables and LNG reinforce the longer‑term narrative.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 5/10
Key Factors
- RSI in overbought territory
- Price near resistance at 52‑week high
- Potential short‑term pullback despite bullish trend
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Bullish MACD and strong cash flow generation
- Attractive dividend yield with sustainable payout
- Analyst consensus “Buy” and ongoing oil price support
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strategic diversification into renewables and LNG
- Stable dividend income stream
- Regulatory and energy‑transition headwinds balanced by scale
Key Metrics & Analysis
Financial Health
Revenue Growth-3.30%
Profit Margin6.68%
P/E Ratio14.3
ROE10.19%
ROA5.07%
Debt/Equity43.15
P/B Ratio141.6
Op. Cash Flow£42.9B
Free Cash Flow£21.6B
Industry P/E20.5
Technical Analysis
TrendBullish
RSI76.4
Support£2,811.50
Resistance£3,227.00
MA 20£2,992.70
MA 50£2,835.97
MA 200£2,725.28
MACDBullish
VolumeIncreasing
Fear & Greed Index100
Valuation
Fair Value£4,518.98
Target Price£3,160.98
Upside/Downside-1.44%
GradeOvervalued
TypeBlend
Dividend Yield3.50%
Risk Assessment
Beta0.24
Volatility21.69%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.